{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Study Responsibility', 'Organization', 'Clinical drug supply and distribution', 'Immunogenicity and PK Laboratory', 'Central safety laboratory', 'Biomarker analysis laboratory', 'Data Safety Monitoring Board Managing', 'Organization', '7 INTRODUCTION', '7.1', 'Background', '7.1.1 Thyroid Eye Disease', \"Thyroid eye disease (TED), also termed Graves' ophthalmopathy/orbitopathy (GO) and\", 'thyroid-associated ophthalmopathy (TAO), is an autoimmune condition commonly associated', \"with Graves' hyperthyroidism/disease, but also occurs in a proportion of patients with other\", \"autoimmune thyroid diseases, including Hashimoto's thyroiditis. TED is divided by severity into\", 'mild, moderate, and severe disease, with moderate-to-severe disease representing 25-50% of', 'cases [Bartley, 1994; Noth et al, 2001; Tanda et al, 2013]. In terms of time course, TED can be', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 45 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'considered as 2 distinct conditions: \"active TED,\" which is an autoimmune inflammatory', 'response targeting orbital soft tissues; and \"inactive TED,\" which is the name given to the', 'expanded and fibrotic tissues that are the sequelae of the active disease. Active TED typically', 'lasts 1 to 3 years, and then the inflammation spontaneously subsides to leave the permanent', 'pathology of inactive TED [Burch et al, 1993].', 'The annual incidence rate of TED in the US has been estimated to be 16 cases per 100,000', 'people for women and 2.9 cases per 100,000 people for men [Bartley, 1994]. The incidence', 'appears to be comparable in Europe [Abraham-Nordling et al, 2011; Mostbeck et al, 1998; Noth', 'et al, 2001; Tanda et al, 2013]. Patients aged between 30 and 50 years are most frequently', 'affected, with severe cases more frequent in those older than 50 years [Dickinson, 2010]. The', 'occurrence and severity of TED is associated with smoking [Prummel et al, 1993].', 'A mounting body of evidence in the scientific literature indicates that the pathophysiology of', 'active TED involves the autoimmune activation and proliferation of orbital fibroblasts [Bahn,', '2010; Boschi et al, 2005; Smith, 2010]. The activation of fibroblasts triggers release of', 'inflammatory cytokines, infiltration of immune cells into orbital soft tissues (muscle, interstitial', 'and adipose), excessive synthesis of extracellular matrix, and tissue expansion and remodeling', '(ibid). Clinical features of moderate-to-severe TED include orbital pain, swelling, dry eye,', 'redness and discomfort of the lids and ocular surface, thickening and retraction of the eyelids,', 'and proptosis (exophthalmos) due to the expansion of tissue behind the eye [Bahn, 2010; Burch', 'et al, 1993; Dickinson, 2010; Mallika et al, 2009].', 'In its moderate-to-severe form, TED has high morbidity [Bartalena et al, 2008; Bartley, 1994;', 'Dickinson, 2010; Gerding et al, 1997]. Morbidity takes the form of orbital pain, together with a', 'number of serious, sight-threatening conditions, including diplopia (due to inability to correctly', 'align the eyes), corneal ulceration (due to inability to close lids), and dysthyroid optic neuropathy', '(due to proptosis, tissue crowding, and stress on the optic nerve). These combine to produce', 'marked reductions in quality of life (QoL) (e.g., physical functioning, role functioning, social', 'functioning, mental health, health perceptions, and pain) [Gerding et al, 1997; C. Terwee et al,', '2002]. TED can also produce profound psychosocial problems, in particular anxiety and', 'depression, due to the alarming and disfiguring changes in appearance [Bartley et al, 1996;', 'Coulter et al, 2007; G. J. Kahaly et al, 2005]. Taken together, these data show that moderate-to-', 'severe active TED is a physically and emotionally debilitating condition (Figure 7.1).', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 46 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'For mild active TED, \"watchful waiting\" is considered appropriate for a proportion of patients,', 'especially those with a satisfactory QoL [Bartalena et al, 2000]. In the mild condition, signs and', 'symptoms can resolve leaving minor or no clinically relevant sequelae as inactive TED. In', 'contrast, moderate-to-severe active TED often requires prompt treatment [Burch et al, 1993; G.J.', 'Kahaly, 2010]. There are no approved therapies. Currently, the most commonly used medical', 'therapies for moderate-to-severe active TED are high-dose corticosteroids [Bartalena et al, 2012;', 'G.J. Kahaly, 2010], and in recent years rituximab [Salvi et al, 2015; Silkiss et al, 2010], neither', 'of which is approved for treatment of TED. The most common nonmedical methods for treating', 'moderate-to-severe active TED are orbital radiation and emergency decompression surgeries', '[Baril et al, 2014; Prummel et al, 2004]. All treatments for moderate-to-severe active TED are', 'viewed as suboptimal due to inadequate efficacy and significant tolerability issues and safety', 'concerns [Bartalena et al, 2012; Gasinska et al, 2012; Gorman et al, 2001; Melamud et al, 2014;', 'Perez et al, 2014; Poetker et al, 2010; Stan et al, 2015; Zang et al, 2011]. Inactive TED is treated', 'by rehabilitative and cosmetic surgeries, with the goal to reduce proptosis, correct strabismus,', 'minimize eyelid retraction, and address disfiguration [Baldeschi, 2010]. Surgical treatment of', 'inactive TED is essentially an attempt to repair the damage done by the active disease once it has', 'run its course.', 'It is widely stated in the literature that there is significant unmet medical need in TED, and', 'specifically that novel pharmacotherapies with improved efficacy and better tolerability are', 'needed to treat active disease [Bahn, 2012; Bartalena, 2013; Bartalena et al, 2000; Coulter et al,', '2007; Naik et al, 2010; Stan et al, 2015; C. Terwee et al, 2002].', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 47 of 117']\n\n###\n\n", "completion": "END"}